Senior insider sale
Chief Financial Officer at VIKING THERAPEUTICS, INC. — senior position signals high conviction
$2.07M
267.28K shares
What this filing means
ZANTE GREG plans to sell 267.28K shares of VIKING THERAPEUTICS, INC. valued at approximately $2.07M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 4/17/2023ACC: 0001838112-23-000002
Officer· Chief Financial Officer
Since Jan 2021
267.28K
Shares to sell
$2.07M
Approx. market value
7.48K
Acquired (3 months)
1
Planned
4 completed
Securities Acquired — Last 3 Months2
NQ Grant
N/A
8/31/2018
303.00ISO Grant
N/A
8/31/2018
7.18KTotal acquired7.48K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
8/31/2018 | NQ Grant N/A | 303.00 | — |
8/31/2018 | ISO Grant N/A | 7.18K | — |
| Total | 7.48K | ||
Planned & Completed Dispositions5
Completed
—Completed
Units to sell
41.54K
Market value
$149.3K
4/12/2023
—Completed
Units to sell
56.30K
Market value
$149.3K
4/11/2023
—Completed
Units to sell
30.91K
Market value
$147.8K
4/3/2023
—Completed
Units to sell
131.03K
Market value
$1.48M
3/30/2023
Planned — Approximate Date
NASDAQPlanned
Units to sell
7.50K
Market value
$150.0K
4/17/2023
Total
Units
267.28K
Value
$2.07M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
4/12/2023 | 41.54K | $149.3K | — | Completed |
4/11/2023 | 56.30K | $149.3K | — | Completed |
4/3/2023 | 30.91K | $147.8K | — | Completed |
3/30/2023 | 131.03K | $1.48M | — | Completed |
| Planned — Approximate Date | ||||
4/17/2023 | 7.50K | $150.0K | NASDAQ | Planned |
| Total | 267.28K | $2.07M | ||